Evidence map›Paper›PMID 40136978›Full record

ArticleBiosensors2025

Dynamic Plasmonic Coupling in Gold Nanosphere Oligomers: Mechanically Tuned Red and Blue Shifts for SERS/SEF.

István Tóth, Cosmin Farcău

Abstract read
In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

István TóthNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat, 400293 Cluj-Napoca, Romania.ORCID 0000-0002-6771-4388
Cosmin FarcăuNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donat, 400293 Cluj-Napoca, Romania.ORCID 0000-0001-8602-0771

Funding

Romanian Ministry of Education and Research PN-III-P4-ID-PCE-2020-1607Romanian MINISTRY OF RESEARCH, INNOVATION AND DIGITALIZATION PN 23 24 01 02
6 · The paper itself

Abstract

Controlling the surface plasmon resonances of metal nanostructures is crucial for advancing numerous high-sensitivity optical (bio)sensing applications. Furthermore, dynamically adjusting these resonances enables real-time tuning of the spectrum of enhanced electromagnetic fields in the near field, thereby regulating the optical interactions between molecules and the metal surface. In this study, we investigate the plasmonic behavior of linear oligomers composed of gold nanospheres using finite-difference time-domain electromagnetic simulations. The extinction spectra of linear arrangements such as dimers, trimers, and quadrumers are obtained for different sphere sizes, interparticle gaps, and polarization of the incident light. In view of (bio)sensing applications based on plasmon-enhanced optical spectroscopy such as surface-enhanced Raman/fluorescence (SERS/SEF), the sensitivity of various coupled plasmon modes to the variation of the interparticle gap is evaluated. The achievement of both red-shifting and blue-shifting plasmon modes offers ways to mechanically control the optical response of the linear oligomers in real-time and design new optical sensing protocols. Based on these findings, both an approach for trapping molecules into SERS hotspots and an approach for dual-mode SERS/SEF using a single excitation wavelength are proposed, contributing to the future development of (bio)sensing protocols.

Indexed as

Biosensing TechniquesGoldMetal NanoparticlesNanospheresSpectrum Analysis, RamanSurface Plasmon ResonanceGolddynamic tuningmolecular sensingplasmonic oligomers

Identifiers

PMID40136978
PMCPMC11940356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.